Quidel Signs Retail Distribution Agreement to Increase Access to At-Home COVID-19 Testing
Quidel Corporation (NASDAQ: QDEL) (“Quidel”), a leading provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that it has completed a distribution and fulfillment agreement with McKesson Corporation, a global leader in healthcare supply chain management solutions and retail pharmacy, to expedite consumer access to Quidel’s non-prescription QuickVue At-Home OTC COVID-19 Test.
The agreement with distribution leader McKesson will enable Quidel to continue to supply existing customers in the professional segment and also reach significant new markets as the company introduces its new over-the-counter COVID-19 antigen product for retail markets and testing for reopening schools, and for health departments, employers, entertainment centers, and many other locations. McKesson will be Quidel’s lead commercial partner in fulfilling QuickVue At-Home OTC COVID-19 rapid antigen test orders to individuals and businesses with the following support:
- Access to multiple retailers, where McKesson will accelerate our product roll-out strategy.
- Availability to McKesson’s Health Mart franchise, allowing Quidel access to a network of over 5,000 independent pharmacies.
- E-commerce support; ability to rapidly introduce products across multiple e-commerce sites, such as Amazon, eBay, and Simply Medical, McKesson’s home health e-commerce site.
“We are pleased to partner with McKesson, expecting to leverage McKesson’s ability to sell and distribute QuickVue through online channels like Amazon, WalMart.com, and through retail pharmacies, including their network of independent Health Mart pharmacies, grocery outlets, as well as health systems and other medical providers,” said Douglas Bryant, president and CEO of Quidel Corporation. “This distribution agreement is intended to expedite broad availability of our QuickVue At-Home OTC COVID-19 Test for families, schools and businesses and help Quidel meet our goal of democratizing access to affordable antigen testing. We are proud that the combined strength of our two companies working in partnership can truly advance individual and public health.”